Propanc Biopharma (PPCB) Registration filing summary

Company overview and business model

• Focuses on developing novel cancer treatments targeting pancreatic, ovarian, and colorectal cancers using a proprietary proenzyme therapy (PRP) designed to prevent recurrence and metastasis.

• Lead product PRP is in preclinical development, with plans for a Phase Ib clinical trial in advanced solid tumors, subject to financing.

• Holds a significant intellectual property portfolio with 85 granted or allowed patents and 5 applications in key jurisdictions.

• Operates primarily from Australia, with research collaborations in Europe and a small team supported by consultants.

Financial performance and metrics

• No revenue-generating operations to date; accumulated deficit of $121.6 million as of March 31, 2025.

• Net loss of $54.9 million for the nine months ended March 31, 2025, driven by $51.3 million in stock-based compensation and consulting expenses.

• Cash balance of $50,760 as of March 31, 2025; current liabilities of $4.3 million, including $438,578 in convertible notes and $366,029 in related party loans.

• Negative cash flows from operations; ongoing reliance on debt and equity financings to fund activities.

Use of proceeds and capital allocation

• Estimated net proceeds of $4.6 million from the offering (or $5.29 million if over-allotment is exercised), primarily allocated to working capital and general corporate purposes.

• Management retains broad discretion over allocation; proceeds may be invested in short-term, interest-bearing instruments until used.